NHG-JHSI focuses on joint research collaborations for advanced drug trials, development of new capabilities in Medical Oncology as well as expertise knowledge-sharing projects.
On 3 January 2018, the National Healthcare Group (NHG) and Johns Hopkins Medicine International (JHI) announced the formation of the new NHG-Johns Hopkins Singapore Institute (NHG-JHSI). The Institute represents a new phase of the long withstanding partnership between NHG and JHI, which started with Johns Hopkins Singapore International Medical Centre (JHSIMC) who had provided private and public oncology services to the people of Singapore, regionally and beyond for the past 20 years.
With both organisations sharing a common vision to advance cancer care in Singapore, Oncology services and specialised staff from JHSIMC have transitioned to come under Tan Tock Seng Hospital (TTSH), the flagship of NHG – one of the largest public healthcare groups in Singapore. This transition of Oncology clinical services from JHSIMC to TTSH serves to integrate and broaden the care spectrum for patients and focus on the population health needs for Singapore.
With the provision of Medical Oncology care now directly under TTSH, NHG-JHSI will focus on joint research collaborations for advanced drug trials, development of new capabilities in Medical Oncology as well as expertise knowledge-sharing projects such as Precision Medicine with Johns Hopkins in the United States.
To find out more, please visit TTSH website.
This article was last reviewed on
Tuesday, March 22, 2022
Community Health Assist Scheme (CHAS) Singapore
Seniors’ Mobility and Enabling Fund
Enhancement for Active Seniors (EASE) by HDB
In partnership with